Literature DB >> 35586432

Novel Cyclic Cyanoenone Derivatives as KEAP1Modulators for Treating Neurodegenerative Diseases.

Ram W Sabnis1.   

Abstract

Entities:  

Year:  2022        PMID： 35586432      PMCID： PMC9109512          DOI： 10.1021/acsmedchemlett.2c00156

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.632


× No keyword cloud information.
  5 in total

Review 1.  The principal molecular mechanisms behind the activation of Keap1/Nrf2/ARE pathway leading to neuroprotective action in Parkinson's disease.

Authors:  Amritha Chakkittukandiyil; Deepak Vasudevan Sajini; Arjunan Karuppaiah; Divakar Selvaraj
Journal:  Neurochem Int       Date:  2022-03-09       Impact factor: 3.921

Review 2.  The potential roles of Nrf2/Keap1 signaling in anticancer drug interactions.

Authors:  Jingya Wang; Jin Yang; Mingnan Cao; Zhigang Zhao; Baoshan Cao; Siwang Yu
Journal:  Curr Res Pharmacol Drug Discov       Date:  2021-05-04

Review 3.  Nrf2/Keap1/ARE signaling: Towards specific regulation.

Authors:  Alexey V Ulasov; Andrey A Rosenkranz; Georgii P Georgiev; Alexander S Sobolev
Journal:  Life Sci       Date:  2021-10-31       Impact factor: 5.037

Review 4.  Cyclobutanes in Small-Molecule Drug Candidates.

Authors:  Marnix R van der Kolk; Mathilde A C H Janssen; Floris P J T Rutjes; Daniel Blanco-Ania
Journal:  ChemMedChem       Date:  2022-03-29       Impact factor: 3.540

Review 5.  Mitophagy in Huntington's disease.

Authors:  I Šonský; P Vodička; K Vodičková Kepková; H Hansíková
Journal:  Neurochem Int       Date:  2021-07-28       Impact factor: 3.921
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.